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Free radicals are chemical species containing one or more un-
paired electrons, most of them being unstable and capable of
abstracting electrons from other molecules. The predominant
reactive oxygen species generated by cell metabolism or by
exogenous factors include hydrogen peroxide (H2O2), the hy-
droxyl radical (HO), the superoxide anion radical (HOA).
These free radicals have essential roles in cell signaling, apop-
tosis and gene expression. On the other hand, excessive freeradical attack can damage DNA, proteins and lipids, resulting
in diseases like cancer, neurological degeneration and arthritis,
as well as the process of aging (Halliwell and Gutteridge, 1990;
Halliwell et al., 1992). Therefore, considerable speculation has
been directed towards the identiﬁcation of antioxidants for use
in preventive medicine.
It is well known that, indole derivatives extensively present
in natural products, are very important substances for their
medicinal and biological aspects. Malatonin (MLT) (Tan
et al., 1993) is a highly conserved molecule that it acts as a free
radical scavenger and a broad spectrum antioxidant (Sreejith
et al., 2007). It is known to be a potent in vitro antioxidant
as well powerful in vivo radical scavenger. The indole nucleus
is frequently found in medicinal chemistry and is considered
as privileged scaffolds. Indole analogues constitute an impor-
tant class of therapeutic agents in medicinal chemistry includ-
ing anticancer (Chen et al., 1996), antioxidant (Suzen and
Buyukbingol, 2000), antirheumatoidal (Buyukbingol et al.,
1994) and anti-HIV (Buyukbingol et al., 1994; Suzen and
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system (Lieberman et al., 1997; Page et al., 2007). Many indole
derivatives considered as the most potent scavengers of free
radicals (Chyan et al., 1999). This prompted us to the selection
of indole as starting synthon for the present work.
Pyridinoles have attracted considerable attention because of
their wide range of pharmacological and biological activities.
Pyridinole moieties are used in determination of iron (III) in
multivitamins (Hashem and Abudkar, 2000), provide the hep-
ato-protective activity of coffee (Kurakanene and Igarashi,
2006). They are used as drugs for angina pectoris (David,
1968), antioxidant agents (Masashi et al., 2005) and for treat-
ment of ischemic stroke (Zhang et al., 2008). Also thiazolotriaz-
oles have been reported to possess antibacterial, antifungal,
anti-inﬂammatory (Kulkarni et al., 1981), antimycotic, anti
HIV-1 (Wujec et al., 2004; Syed and Ali, 2008) and anthelmin-
thic activities (Kamal et al., 2008; Habernickel, 1992).
Over the past two decades, pyrazole containing compounds
have received considerable attention owing to their diverse
chemotherapeutic potentials including versatile antineoplastic
activities. Literature survey revealed that some pyrazoles have
been implemented as antileukemic (Daidone et al., 2004;
Manett et al., 2008), antitumor (Li et al., 2006; Xia et al.,
2007, 2008; Farag et al., 2008) and antiproliferative (Schenone
et al., 2004; Daidone et al., 2004) and anticancer activities
(Warshakoon et al., 2006; Huang et al., 2007; Zhu et al., 2007).
Hence, in the design of new drugs, the development of hy-
brid molecules through the combination of different pharma-
cophores in one frame may lead to compounds with
interesting pharmacological proﬁles. Therefore, combination
of indole and pyrazole pharmacophores in the same molecule
is an interesting combination for the development of new phar-
macologically active antioxidant and antimicrobial agents.
Therefore, in continuation of our interest in functionaliza-
tion of indoles (Saundane et al., 2009; Saundane and Veeresh
Sharma, 2004) and in searching of new biologically active indole
analogues, the title compounds were synthesized and screened
for their in vitro antioxidant activity using DPPH radical scav-
enging and reducing power assay and antimicrobial assay.
2. Experimental
All the reagents were obtained commercially and used after
further puriﬁcation. Melting points were determined by an
open capillary method and are uncorrected. The IR (KBr)
spectra were recorded with a Perkin–Elmer spectrum one
FT-IR spectrometer. The 1H NMR (DMSO-d6) spectra re-
corded with an Bruker AVANCE III 500 MHz (AV 500) multi
nuclei solution NMR and the chemical shifts were expressed in
ppm (d scale) downﬁeld from TMS. Mass spectra were re-
corded with a JEOL GCMATE II GC–MS mass spectrometer.
Elemental analysis carried out using Flash EA1112 series ele-
mental analyzer.
2.1. 2-Oxo-4-(20-phenyl-50-substituted 1H-indol-30-yl)-6-
phenylpyridin-3-carbonitriles (2a–c)
A mixture of (1a–c) (0.001 mol) and ethylcyanoacetate
(0.001 mol) in glacial acetic acid (30 ml) containing anhydrous
ammonium acetate (0.002 mol) was reﬂuxed for 8 h. The reac-
tion mixture was then cooled and poured into ice cold water.The formed product was ﬁltered off, washed with water, dried
and recrystallized from ethanol.
2.2. 2-Oxo-4-(20-phenyl-50-chloro-1H-indol-30-yl)-6-
phenylpyridin-3-carbonitrile 2a
74% yield Yellow crystals. m.p. 245–246 C. IR (KBr): t 3300
(indole NH), 3264 (NH), 2206 (CN), 1677 (CO). 1H NMR
(DMSO-d6): d= 12.1 (s, 1H, indole NH), 9.5 (s, 1H, NH),
7.2–8.2 (m, 14H, ArH) ppm; MS: (m/z) = 421, 423 (M+,
M++2). Anal. for C26H16N3OCl: calcd. C, 74.11, H 3.80, N
9.98; Found: C 74.22, H 3.99, N 10.13.
2.3. 2-Oxo-4-(20-phenyl-50-methyl-1H-indol-30-yl)-6-
phenylpyridin-3-carbonitrile 2b
72% yield Yellow powder. m.p. 239–240 C. IR (KBr): t 3303
(indole NH), 3268 (NH), 2201 (CN), 1687 (CO). 1H NMR
(DMSO-d6): d= 12.0 (s, 1H, indole NH), 9.6 (s, 1H, NH),
7.2–8.3 (m, 14H, ArH), 2.1 (s, 3H, CH3) ppm; MS: (m/
z) = 401. Anal. for C27H19N3O: calcd. C, 80.80, H 4.74, N
10.47; Found: C 80.65, H 4.85, N 10.13.
2.4. 2-Oxo-4-(20-phenyl-1H-indol-30-yl)-6-phenylpyridin-3-
carbonitrile 2c
71% yield Yellow powder. m.p. 242–240 C. IR (KBr): t 3307
(indole NH), 3259 (NH), 2209 (CN), 1682 (CO). 1H NMR
(DMSO-d6): d= 12.1 (s, 1H, indole NH), 9.5 (s, 1H, NH),
7.1–8.2 (m, 15H, ArH) ppm; MS: (m/z) = 387. Anal. for
C26H17N3O: calcd. C, 80.62, H 4.39, N, 10.85; Found: C
80.82, H 4.48, N 11.02.
2.5. [3-Cyano-6-phenyl-4-(20-phenyl-50-substituted 1H-indol-30-
yl)pyridin-2-yloxy]-acetic acid ethyl ester 3a–c
A mixture of compound (2a–c) (0.001 mol) and ethyl chloro-
acetate (0.002 mol) in dry acetone (40 ml) containing sodium
acetate (0.001 mol) was reﬂuxed for 7 h. The solvent was re-
moved under vaccum, the residue was poured in cold water
to remove inorganic solids, ﬁltered to obtain compound (3a–
c) and recrystallized from 1,4-dioxane.
2.6. 3-Cyano-6-phenyl-4-(20-phenyl-50-chloro-1H-indol-30-
yl)pyridin-2-yloxy]-acetic acid ethyl ester 3a
69% yield Pale yellow powder. m.p. 198–199 C. IR (KBr): t
3265 (indole NH), 2210 (CN), 1674 (CO). 1H NMR (DMSO-
d6): d= 11.5 (s, 1H, indole NH), 7.1–8.1 (m, 14H, ArH), 4.9
(s, 2H, CH2), 4.1 (q, 2H, CH2), 1.6 (t, 3H, CH3) ppm; MS:
(m/z) = 507, 509 (M+, M++2). Anal. for C30H22N3O3Cl:
calcd. C, 71.00, H 4.34, N 8.28; Found: C 71.21, H 4.25, N
8.41.
2.7. [3-Cyano-6-phenyl-4-(20-phenyl-50-methyl-1H-indol-30-
yl)pyridin-2-yloxy]-acetic acid ethyl ester 3b
68% yield Pale yellow powder. m.p. 185–186 C. IR (KBr): t
3269 (indole NH), 2216 (CN), 1680 (CO). 1H NMR (DMSO-
d6): d= 11.6 (s, 1H, indole NH), 7.1–8.0 (m, 14H, ArH),
4.89 (s, 2H, CH2), 4.2 (q, 2H, CH2), 2.2 (s, 3H, CH3), 1.7 (t,
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C, 76.39, H 5.13, N, 8.62; Found: C 76.52, H, 5.26, N 8.75.2.8. [3-Cyano-6-phenyl-4-(20-phenyl-1H-indol-30-yl)pyridin-2-
yloxy]-acetic acid ethyl ester 3c
69% yield Pale yellow powder. m.p. 180–181 C. IR (KBr): t
3262 (indole NH), 2214 (CN), 1678 (CO). 1H NMR (DMSO-
d6): d= 11.4 (s, 1H, indole NH), 7.1–8.0 (m, 15H, ArH),
4.89 (s, 2H, CH2), 4.0 (q, 2H, CH2), 1.6 (t, 3H, CH3) ppm;
MS: (m/z) = 473 Anal. for C30H23N3O3: calcd. C, 76.10, H
4.86, N, 8.88; Found: C 76.21, H 4.59, N 8.98.2.9. 5-{[3-Cyano-4-(20-phenyl-50-substituted 1H-indol-30-yl)-6-
phenylpyridin-2-yloxy]methyl}-2H-1,2,4-triazol-3(4H)-thiones
4a–c
A mixture of compound (3a–c) (0.0001 mol) and thiosemicar-
bazide (0.0002 mol) in pyridine (20 ml) was reﬂuxed for 5 h.
The mixture was then cooled to room temperature and poured
into ice cold water and acidiﬁed with few drops of acetic acid.
The formed solid was ﬁltered, washed with water dried and
recrystallized from ethanol.2.10. 5-{[3-Cyano-4-(20-phenyl-50-chloro-1H-indol-3-yl)-6-
phenylpyridin-20-yloxy]methyl}-2H-1,2,4-triazol-3(4H)-thione
4a
65% yield Brown solid. m.p. 285–286 C. IR (KBr): t 3180
(NH), 3132 (indole NH), 3105 (NH), 2206 (CN). 1H NMR
(DMSO-d6): d= 11.6 (s, 1H, indole NH), 10.0 (s, 1H, triazole
NH), 9.6 (s, 1H, triazole NH), 7.1–7.9 (m, 14H, ArH), 4.0 (s,
2H, CH2) ppm; MS: (m/z) = 534, 536 (M
+, M++2). Anal.
for C29H19N6OSCl: calcd. C, 65.17, H 3.56, N 15.73; Found:
C 65.31, H 3.71, N 15.92.2.11. 5-{[3-Cyano-4-(20-phenyl-50-methyl-1H-indol-30-yl)-6-
phenylpyridin-2-yloxy]methyl}-2H-1,2,4-triazol-3(4H)-thione
4b
68% yield Brown solid. m.p. 276–278 C. IR (KBr): t 3182
(NH), 3135 (indole NH), 3110 (NH), 2214 (CN). 1H NMR
(DMSO-d6): d= 11.5 (s, 1H, indole NH), 10.1 (s, 1H, triazole
NH), 9.5 (s, 1H, triazole NH), 7.1–7.8 (m, 14H, ArH), 4.1 (s,
2H, CH2), 2.2 (s, 3H, CH3) ppm; MS: (m/z) = 514. Anal. for
C30H22N6OS: calcd. C, 70.04, H 4.28, N 16.34; Found: C
70.25, H 4.53, N 16.13.2.12. 5-{[3-Cyano-4-(20-phenyl-1H-indol-30-yl)-6-
phenylpyridin-2-yloxy]methyl}-2H-1,2,4-triazol-3(4H)-thione
4c
64% yield Brown solid. m.p. 281–282 C. IR (KBr): t 3187
(NH), 3125 (indole NH), 3103 (NH), 2209 (CN). 1H NMR
(DMSO-d6): d= 11.5 (s, 1H, indole NH), 10.0 (s, 1H, triazole
NH), 9.5 (s, 1H, triazole NH), 7.2–7.9 (m, 15H, ArH), 4.1 (s,
2H, CH2) ppm; MS: (m/z) = 534. Anal. for C29H20N6OS:
calcd. C, 69.60, H 4.00, N 16.80; Found: C 69.31, H 4.11, N
16.72.2.13. 2-(6-Oxo-5,6-dihydro-thiazolo[3,2,-b][1,2,4]triazol-2-yl
methoxy)-4-(20-phenyl-50-substituted 1H-indol-30-yl)-6-
phenylpyridine-3-carbonitriles 5a–c
Compound (4a–c) (0.0001 mol) and chloroacetic acid
(0.0001 mol) were reﬂuxed in glacial acetic acid (9 ml) and ace-
tic anhydride (3 ml) mixture for 4 h. Then the reaction mixture
was cooled to room temperature and poured on to crushed ice.
The formed solid was ﬁltered, washed with water, dried and
recrystallized from ethanol.
2.14. 2-(6-Oxo-5,6-dihydro-thiazolo[3,2,-b][1,2,4]triazol-2-yl
methoxy)-4-(20-phenyl-50-chloro-1H-indol-30-yl)-6-
phenylpyridin-3-carbonitrile 5a
69% yield Pale yellow crystals. m.p. 165–166 C. IR (KBr): t
3265 (indole NH), 2216 (CN), 1713 (CO). 1H NMR (DMSO-
d6): d= 11.6 (s, 1H, indole NH), 7.1–8.1 (m, 14H, ArH), 5.0
(s, 2H, CH2), 4.0 (s, 2H, thiazole CH2) ppm; MS: (m/
z) = 574, 576 (M+, M++2). Anal. for C31H19N6O2SCl: calcd.
C, 64.80, H 3.31, N 14.63; Found: C 64.92, H 3.43, N 14.82.
2.15. 2-(6-Oxo-5,6-dihydro-thiazolo[3,2,-b][1,2,4]triazol-2-yl
methoxy)-4-(20-phenyl-50-methyl-1H-indol-30-yl)-6-
phenylpyridin-3-carbonitrile 5b
68% yield. Pale yellow crystals m.p. 169–170 C. IR (KBr): t
3260 (indole NH), 2212 (CN), 1715 (CO). 1H NMR (DMSO-
d6): d= 11.5 (s, 1H, indole NH), 7.1–8.0 (m, 14H, ArH), 5.1
(s, 2H, CH2), 4.1 (s, 2H, thiazole CH2), 2.3 (s, 3H, CH3)
ppm; MS: (m/z) = 554. Anal. for C32H22N6O2S: calcd. C,
69.31, H 3.97, N 15.16; Found: C 69.56, H 3.53, N 15.32.
2.16. 2-(6-Oxo-5,6-dihydro-thiazolo[3,2,-b][1,2,4]triazol-2-yl
methoxy)-4-(20-phenyl-1H-indol-30-yl)-6-phenylpyridin-3-
carbonitrile 5c
65% yield. Pale yellow powder m.p. 162–163 C. IR (KBr): t
3263 (indole NH), 2215 (CN), 1717 (CO). 1H NMR (DMSO-
d6): d= 11.6 (s, 1H, indole NH), 7.2–8.0 (m, 15H, ArH), 5.0
(s, 2H, CH2), 4.2 (s, 2H, thiazole CH2) ppm; MS: (m/
z) = 540. Anal. for C31H20N6O2S: calcd. C, 68.89, H 3.70, N
15.56; Found: C 68.76, H 3.63, N 15.39.
2.17. [3-Cyano-6-phenyl-4-(20-phenyl-50-substituted 1H-indol-
30-yl)pyridin-2-yloxy]-acetic acid hydrazides 6a–c
A mixture of compound (3a–c) (0.0001 mol) and hydrazine hy-
drate (99%) (0.0004 mol) was reﬂuxed in 1,4-dioxane (30 ml)
for 5 h. The excess of solvent was removed under reduced pres-
sure. After cooling, the formed product was ﬁltered off,
washed with cold 1,4-dioxane, dried and recrystallized from
methanol.
2.18. [3-Cyano-6-phenyl-4-(20-phenyl-50-chloro-1H-indol-30-
yl)pyridin-2-yloxy]-acetic acid hydrazide 6a
71% yield. Yellow crystals m.p. 210–211 C. IR (KBr): t 3418
(NH2), 3260 (indole NH), 3141 (NH), 2211 (CN), 1680 (CO).
1H NMR (DMSO-d6): d= 11.5 (s, 1H, indole NH), 8.3 (s,
1H, CONH), 7.2–8.0 (m, 14H, ArH), 4.8 (s, 2H, CH2) ppm;
S504 A.R. Saundane, Y. ManjunathaMS: (m/z) = 493, 495 (M+, M++2) Anal. for C28H20N5O2Cl:
calcd. C, 68.15, H 4.06, N 14.20; Found: C 68.29, H 4.19, N
14.35.2.19. [3-Cyano-6-phenyl-4-(20-phenyl-50-methyl-1H-indol-30-
yl)pyridin-2-yloxy]-acetic acid hydrazide 6b
72% yield. Yellow crystals m.p. 215–216 C. IR (KBr): t 3419
(NH2), 3263 (indole NH), 3148 (NH), 2217 (CN), 1685 (CO).
1H NMR (DMSO-d6): d= 11.6 (s, 1H, indole NH), 8.4
(CONH), 7.2–8.1 (m, 14H, ArH), 4.7 (s, 2H, CH2), 2.3 (s,
3H, CH3) ppm; MS (m/z) = 473. Anal. for C29H23N5O2: calcd.
C, 73.57, H 4.86, N 14.80; Found: C 73.35, H 4.59, N 14.65.2.20. [3-Cyano-6-phenyl-4-(20-phenyl-1H-indol-30-yl)pyridin-2-
yloxy]-acetic acid hydrazide 6c
71% yield. Yellow crystals m.p. 205–207 C. IR (KBr): t 3412
(NH2), 3262 (indole NH), 3144 (NH), 2218 (CN), 1686 (CO).
1H NMR (DMSO-d6): d= 11.4 (s, 1H, indole NH), 8.4
(CONH), 7.2–7.9 (m, 15H, ArH), 4.9 (s, 2H, CH2) ppm; MS:
(m/z) = 459. Anal. for C28H21N5O2: calcd. C, 73.20, H 4.58,
N 15.25; Found: C 73.36, H 4.69, N 15.35.2.21. 1-{2-[4-(20-Phenyl-50-substituted 1H-indol-30-yl)-3-cyano-
6-phenylpyridin-2-yloxy]acetyl}-1,2-dihydro-3-methylpyrazol-
5-ones 7a–c
A mixture of compound (6a–c) (0.0001 mol), ethylacetoacetate
(0.0001 mol), anhydrous NaHCO3 (0.8 g), and anhydrous
Na2SO4 (0.8 g) in 1,4-dioxane (35 ml) was reﬂuxed for 10 h.
Then excess of solvent was removed under reduced pressure,
cooled to room temperature and the residue was poured into
ice cold water. The product thus separated was ﬁltered, washed
with water and recrystallized from 1,4-dioxane.2.22. 1-{2-[4-(20-Phenyl-50-chloro-1H-indol-30-yl)-3-cyano-6-
phenylpyridin-2-yloxy]acetyl}-1,2-dihydro-3-methylpyrazol-5-
one 7a
65% yield. Yellow needles m.p. 256–257 C. IR (KBr): t 3264
(indole NH), 3100 (NH), 2216 (CN), 1713 (CO), 1702 (CO).
1H NMR (DMSO-d6): d= 11.4 (s, 1H, indole NH), 10.0 (s,
1H, NH), 7.1–8.2 (m, 15H, 14ArH, pyrazolone-H), 4.9 (s,
2H, CH2), 1.6 (s, 3H, CH3) ppm; MS: (m/z) = 559, 561
(M+, M++2) Anal. for C32H22N5O3Cl: calcd. C, 68.69, H
3.94, N 12.52; Found: C 68.85, H 4.02, N 12.68.2.23. 1-{2-[4-(20-Phenyl-50-methyl-1H-indol-30-yl)-3-cyano-6-
phenylpyridin-2-yloxy]acetyl}-1,2-dihydro-3-methylpyrazol-5-
one 7b
64% yield. Yellow needles. m.p. 261–262 C. IR (KBr) t: 3268
(indole NH), 3110 (NH), 2220 (CN), 1715 (CO), 1695 (CO).
1H NMR (DMSO-d6): d= 11.5 (s, 1H, indole NH), 10.1 (s,
1H, NH), 7.0–8.2 (m, 15H, 14ArH, pyrazolone-H), 4.8 (s,
2H, CH2), 1.6 (s, 3H, CH3), 2.2 (s, 3H, CH3) ppm; MS: (m/
z) = 539. Anal. for C33H25N5O3: calcd. C, 73.47, H 4.64, N
12.99; Found: C 73.63, H 4.82, N 12.78.2.24. 1-{2-[4-(20-Phenyl-1H-indol-30-yl)-3-cyano-6-
phenylpyridin-2-yloxy]acetyl}-1,2-dihydro-3-methylpyrazol-5-
one 7c
66% yield. Yellow needles. m.p. 269–270 C. IR (KBr): t 3258
(indole NH), 3105 (NH), 2214 (CN), 1712 (CO), 1698 (CO).
1H NMR (DMSO-d6): d= 11.4 (s, 1H, indole NH), 10.1 (s,
1H, NH), 7.1–8.0 (m, 16H, 15ArH, pyrazolone-H), 4.9 (s,
2H, CH2), 1.6 (s, 3H, CH3) ppm; MS: (m/z) = 525. Anal. for
C32H23N5O3: calcd. C, 73.14, H 4.38, N 13.33; Found: C
73.33, H 4.52, N 13.57.2.25. 1-{2-[3-Cyano-6-phenyl-4-(20-phenyl-50-substituted 1H-
indol-30-yl)pyridin-2-yloxy]acetyl}-3-amino-1H-pyrazol-
5(4H)-ones 8a-c
A mixture of compound (6a–c) (0.0001 mol) ethylcyanoacetate
(0.0001 mol), anhydrous NaHCO3 (0.8 g) and anhydrous
Na2SO4 (0.8 g) in 1,4-dioxane (30 ml) was reﬂuxed for 9 h.
The reaction mixture was cooled to room temperature and
poured onto ice cold water, the solid thus separated was ﬁl-
tered off, washed with cold water, dried and recrystallized
from ethanol.2.26. 1-{2-[3-Cyano-6-phenyl-4-(20-phenyl-50-chloro-1H-indol-
30-yl)pyridin-2-yloxy]acetyl}-3-amino-1H-pyrazol-5(4H)-one
8a
61% yield. Yellow needles. m.p. 221–222 C. IR (KBr): t 3400
(NH2), 3263 (indole NH), 2216 (CN), 1713 (CO), 1690 (CO).
1H NMR (DMSO-d6): d= 11.5 (s, 1H, indole NH), 7.0–8.2
(m, 16H, 14ArH and NH2), 4.9 (s, 2H, OCH2CO), 4.2 (s,
2H, pyrazole CH2CO) ppm; MS: (m/z) = 560, 562 (M
+,
M++2). Anal. for C31H21N6O3Cl: calcd. C, 66.43, H 3.73,
N 15.00; Found: C 64.57, H 3.87, N 15.15.2.27. 1-{2-[3-Cyano-6-phenyl-4-(20-phenyl-50-methyl-1H-indol-
30-yl)pyridin-2-yloxy]acetyl}-3-amino-1H-pyrazol-5(4H)-one
8b
62% yield. Yellow needles. m.p. 225–226 C. IR (KBr): t 3405
(NH2), 3263 (indole NH), 2216 (CN), 1718 (CO), 1695 (CO).
1H NMR (DMSO-d6): d= 11.4 (s, 1H, indole NH), 7.1–8.2
(m, 16H, 14ArH and NH2), 4.8 (s, 2H, OCH2CO), 4.1 (s,
2H, pyrazole CH2CO), 2.3 (s, 3H, CH3) ppm; MS: (m/
z) = 540. Anal. for C32H24N6O3: calcd. C, 71.11, H 4.44, N
15.56; Found: C 71.29, H 4.67, N 15.73.2.28. 1-{2-[3-Cyano-6-phenyl-4-(20-phenyl-1H-indol-30-
yl)pyridin-2-yloxy]acetyl}-3-amino-1H-pyrazol-5(4H)-one 8c
58% yield. Yellow powder. m.p. 216–217 C. IR (KBr): t 3409
(NH2), 3263 (indole NH), 2218 (CN), 1712 (CO), 1696 (CO).
1H NMR (DMSO-d6): d= 11.4 (s, 1H, indole NH), 7.0–8.1
(m, 17H, 15ArH and NH2), 4.8 (s, 2H, OCH2CO), 4.3 (s,
2H, pyrazole CH2CO) ppm; MS:(m/z) = 526. Anal. for
C31H22N6O3: calcd. C, 70.72, H 4.18, N 15.97; Found: C
70.51, H 4.37, N 16.11.
Figure 1 Reducing power of compounds 2–8.
Figure 2 Reducing power of compounds 2–8.
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In the present work, 2-oxo-4-(20-phenyl-50-substituted 1H-
indol-30-yl)-6-phenylpyridin-3-carbnitriles (2a–c) were
conveniently prepared from the reaction of 3-(20-phenyl-50-
substituted 1H-indol-30-yl)-1-phenylprop-2-in-1-ones (1a–c)
with ethylcyanoacetate in acetic acid containing anhydrous
ammonium acetate. Formation of compound 2a was con-
ﬁrmed by its IR, 1H NMR and mass spectral studies. In its
IR spectrum, the band which appeared at 3300, 3264, 2206
and 1677 cm1 were appeared due to NH, indole NH, CN
and C‚O functions, respectively. Where as in 1H NMR spec-
trum, the signals resonated at d 12.1 (s, 1H, indole NH), 9.5 (s,
1H, NH), 7.2–8.2 (m, 14H, ArH) and in mass spectrum isoto-
pic molecular ion peak at m/z 421 and 423 was noticed which
conﬁrms the formation of 2a. Compounds (2a–c) on alkylation
with ethylchloroacetate in basic conditions afforded acetic acid
ethyl esters (3a–c). 3a in its IR spectrum exhibited bands at
3265, 2210 and 1674 cm1 due to indole NH, CN and C‚O
functions, respectively. In 1H NMR spectrum of compound
3a, signals were exhibited at d 11.5 (s, 1H, indole NH), 7.1–
8.1 (m, 14H, ArH), 4.9 (s, 2H, CH2), 4.1 (q, 2H, CH2) and
1.6 (t, 3H, CH3). The isotopic molecular ion peaks were ob-
served at m/z 507 and 509 in its mass spectrum. Cycloconden-
zation of compounds (3a–c) with thiosemicarbazide in boiling
pyridine gave 5-{[3-cyano-4-(20-phenyl-50-substituted 1H-in-
dol-30-yl)-6-phenylpyridin-2-yloxy]methyl}-2H-1,2,4-triazol-
3(4H)-thiones (4a–c). Compound 4a in its IR spectrum exhib-
ited bands at 3132, 3180, 3105 and 2206 due to NH, indole
NH, NH and CN functions, respectively. In its 1H NMR spec-
trum, various protons resonated at d 11.6 (s, 1H, indole NH),
10.0 (s, 1H, triazole NH), 9.6 (s, 1H, triazole NH), 7.1–7.9 (m,
14H, ArH) and 4.0 (s, 2H, CH2). The mass spectrum of 4a
exhibited isotopic molecular ion peaks at m/z 534 and 536,
which conﬁrms the formation of 4a from 3a. Further, com-
pounds (4a–c) on treatment with chloroacetic acid in acetic
acid afforded 2-(6-oxo-5,6-dihydro-thiazolo[3,2-b][1,2,4]tria-
zol-20-yl)-methoxy-4-(20-phenyl-50-substituted 1H-indol-30-yl)-
6-phenylpyridin-3-carbonitriles (5a–c). In IR spectrum of 5a,
peaks at 3265, 2216 and 1713 were due to NH, CN and
C‚O functions, respectively. Where as in its 1H NMR spec-
trum, the various signals found at d 11.6 (s, 1H, indole NH),
7.1–8.1 (m, 14H, ArH), 5.0 (s, 2H, CH2) and 4.0 (s, 2H, thia-
zole CH2), and in its mass spectrum, the isotopic molecular ion
peaks noticed at m/z 574 and 576 conﬁrms the formation of 5a.
On the other hand, compounds (3a–c) on treatment with
hydrazine hydrate gave hydrazide derivatives (6a–c). Com-
pound 6a in its IR spectrum exhibited bands at 3418, 3260,
3141, 2211 and 1680 cm1 due to NH2, NH, indole NH, CN
and C‚O functions, respectively. In its 1H NMR spectrum
the downﬁeld singlets at d 11.5 is attributed to indole NH
and d 8.3 due to CONH protons, where as, the multiplet at
d 7.3–8.0 due to 14 aromatic protons and the upﬁeld singlet
at d 4.8 assigned to two methylene protons. Compound 5a
exhibited isotopic molecular ion peak at m/z 493, 495 conﬁrms
the formation of 6a from 3a. Then, compounds (6a–c) on
cyclocondenzation with ethylacetoacetate in boiling 1,4-diox-
ane gave compounds (7). In the IR spectrum of compound
7a, the absorption bands observed at 3264, 3100, 2216, 1713
and 1702 cm1 due to indole NH, NH, CN, pyrazole CO
and CO functions, respectively. In its 1H NMR spectrumvarious protons resonated at d 11.4 (s, 1H, indole NH), 10.1
(s, 1H, NH), 7.1–8.2 (m, 15H, 14ArH and pyrazole-H), 4.9
(s, 2H, CH2) and 1.6 (s, 3H, CH3). In its mass spectrum, the
isotopic molecular ion peaks were observed at m/z 559 and
561 conﬁrmed the formation of 7a. Also, compounds (6a–c)
on reaction with ethylcyanoacetate in 1,4-dioxane containing
anhydrous sodium bicarbonate, gave pyrazole derivatives
(8a–c). The IR spectrum of compound 8a showed characteris-
tic bands at 3400, 3263, 2216, 1713 and 1690 cm1 due to NH2,
indole NH, CN, pyrazole CO and CO functions, respectively.
In 1H NMR spectrum, the signals at d 11.5 (s, 1H, indole NH),
7.0–8.2 (m, 16H, 14 ArH and NH2), 4.9 (s, 2H, OACH2ACO)
and 4.2 (s, 2H, pyrazole CH2CO) were noticed. The mass spec-
trum of compound 8a showed isotopic molecular ion peaks at
m/z 560, 562 conﬁrmed the formation of 8a (Scheme 1).
4. Antioxidant activity studies
4.1. Ferric ions (Fe3+) reducing antioxidant power (FRAP)
Figs. 1–3 show the reducing power of synthesized compounds
(2–8) examined as a function of their concentration. In this as-
Figure 3 Reducing power of compounds 2–8. Figure 4 DPPH radical scavenging activity of compounds 2–8.
Figure 5 DPPH radical scavenging activity of compounds 2–8.
Figure 6 DPPH radical scavenging activity of compounds 2–8.
S506 A.R. Saundane, Y. Manjunathasay, the yellow color of the test solution changes to various
shades of green and blue depending upon the reducing power
of each compound. The presence of reducer (i.e. antioxidant)
causes the reduction of the Fe+3/Ferricyanide complex to
the ferrous form giving after the addition of trichloroacetic
acid and ferric chloride, the perls Prussian blue that can be
monitored at 700 nm. The reducing power of test compounds
increases with increase in concentration. Compounds 2–6 and
8 exhibited very low absorption, whereas compounds 7a–c
were found to have higher absorption but lower than the
standards.
The presence of enamine and a,b-unsaturated ketonic func-
tions in the pyrazolone moiety in addition to the alkyl group
may play an important role to act as a better electron donor
which may enhance reducing power ability of 7.Where as such
systems are not available in the rest of the test compounds.
Compound 7a exhibited the maximum absorption value com-
pare to 7b and 7c. This may be due to the chloro-substitution
at 5-position of indole, which may be helping for stabilization
of the free radical form after donating electron and thus to
leading maximum reducing ability compared to 7b and 7c.
4.2. Radical scavenging activity (RSA)
Free radical scavenging is one of the best known mechanisms
by which antioxidants inhibit lipid oxidation. 1,1-Diphenyl-2-
picrylhydrazyl (DPPH) radical scavenging activity evaluation
is standard assay in antioxidant activity studies and offers a ra-
pid technique for screening the radical scavenging activity
(RSA) of speciﬁc compounds. The RSA of synthesized com-
pounds (2–8) were tested using methanolic solution of the sta-
ble free radical DPPH. The results of the tested compounds
were shown in Figs. 4–6. The freshly prepared DPPH solution
exhibits a deep purple color with absorption maxima at
517 nm. The purple color generally fades/disappears when an
antioxidant is present in the medium. Thus, antioxidant mole-
cule can quench DPPH free radical (i.e. by providing hydrogen
atoms or by electron donation, conceivably via a free radical
attack on DPPH molecule) and convert them to a colorless/
bleached product, resulting in absorbance at 517 nm. There-
fore, the more rapidly the absorbance decreases, the more po-
tent the antioxidant activity of the compounds. Hence this
method is based on the reduction of alcoholic DPPH solutionin the presence of a hydrogen-donating antioxidant due to the
formation of the non-radical form DPPH-H by the reaction.
In the case of thiazolo[3,2,-b][1,2,4]triazoles derivative 5a,
this showed highest DPPH scavenging activity with percent
Synthesis, antimicrobial and antioxidant activities S507inhibition of 78.85 at concentration of 75 lg/ml, when com-
pared with the other compounds. This increased activity may
be due to existence of the CH2CO group. The presence of cy-
ano group was inadequate for antioxidant activity. All the
compounds containing pyridine ring showed low RSA activity.
Hence presence of cyano and pyridine substituents may drasti-
cally decrease the RSA. None of the compounds showed good
RSA activity than standards (see Scheme 1).
4.3. Antimicrobial activities
The results of antimicrobial activity evaluations (Table 1) re-
veals that substances 4a, 5a and 7b exhibited maximum inhib-
itory activity against Pseudomonas aeruginosa. Compound 4a,
5a and 8a exhibited maximum zone of inhibition against gram
negative bacteria. In addition, compound 4a, 5b and 8a
showed maximum inhibitory growth againstAspergillus oryzae
and compound 5a showed maximum inhibitory growth againstSchemeAspergillus niger. In addition, the results indicate that, rest of
the compounds exhibited moderate growth inhibitory activities
against all the four tested microbes.
The majority of the compounds containing indole, phe-
nyl, 1,2,4-triazole, thiozolo[3,2,-b][1,2,4]triazole and pyrazo-
lone in the ring system that incorporate the pyridine
moiety had growth inhibitory activities. It is worth mention-
ing that compound (4a–c) and (5a–c) possessing 1,2,4-triazole
ring appended to the pyridine ring system via methyloxy-lin-
ker showed a high antibacterial activity. In contrast, attach-
ment of pyrazole nucleus to the pyridine nucleus via
acetyloxy-linker exhibited potent antifungal activity against
the two organisms used. Compound 5a exhibited consistent
antimicrobial activity towards all the organisms tested.
Hence, several synthesized compounds exhibited comparable
activity to the gentamycin and ﬂuconazole. However, none
of the compounds exhibited zone of inhibition more than
the standards.1
Table 1 Antimicrobial activity results of compounds 2–8.
Comp. no. Antibacterial activity (in mm) Antifungal activity (in mm)
P. aeruginosa P. kneumonia A. oryzae A. niger
250
lg/ml
125
lg/ml
62.5
lg/ml
250
lg/ml
125
lg/ml
62.5
lg/ml
250
lg/ml
125
lg/ml
62.5
lg/ml
250
lg/ml
125
lg/ml
62.5
lg/ml
2a 10 10 09 12 12 12 11 11 10 12 12 11
2b 10 09 09 10 10 09 11 10 10 12 12 12
2c 11 11 10 12 10 10 09 10 10 09 09 08
3a 12 12 11 12 12 12 10 10 09 10 10 10
3b 11 11 10 13 12 12 09 08 08 10 10 08
3c 12 11 11 10 10 09 08 08 07 07 06 06
4a 13 13 13 14 14 13 13 13 13 11 10 10
4b 10 10 10 09 07 06 11 11 11 10 10 09
4c 09 08 06 07 07 07 10 09 09 12 12 11
5a 13 13 12 14 14 13 12 12 12 13 13 12
5b 09 09 07 12 11 12 13 13 12 12 11 11
5c 07 07 06 10 09 09 11 11 10 10 10 09
6a 12 12 12 12 12 12 11 11 11 11 11 10
6b 12 12 12 10 09 08 10 09 09 10 10 09
6c 10 10 09 09 07 07 10 10 10 09 08 08
7a 12 11 11 10 09 09 12 12 12 12 12 12
7b 13 13 13 08 07 07 10 09 09 11 11 10
7c 10 09 09 08 07 07 10 11 11 08 08 07
8a 11 11 09 14 13 13 13 13 12 10 10 10
8b 10 10 10 13 13 13 12 12 12 08 08 08
8c 09 08 08 11 10 10 10 09 09 08 07 07
Std. I 15 14 14 16 16 15 – – – – – –
Std. II – – – – – – 14 14 15 14 14 15
Std. I: Gentamycin; Std. II: Flucanozole.
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5.1. Reducing power assay
The reducing power of the synthesized compounds was deter-
mined according to the method of Oyaizu (1986). Different
concentrations of the samples (25–100 lg/ml) in DMSO
(1 ml) were mixed with phosphate buffer (2.5 ml, 0.2 mol,
pH = 6.6) and potassium ferricyanide (2.5 ml, 1%). The mix-
ture was incubated at 50 C for 20 min. after which a portion
(2.5 ml) of trichloroacetic acid (10%) was added to the mix-
ture, which was then centrifuged for 10 min. at 1000g. The
upper layer of solution (2.5 ml) was mixed with distilled water
(2.5 ml) and FeCl3 (0.5 ml, 0.1%), and then the absorbance at
700 nm was measured in a spectrophotometer. BHA, TBHQ
and ascorbic acid (A. A) were used as standards.5.2. Radical scavenging activity (RSA) assay
The free radical scavenging activity of ( 2a–c)– (8a–c) was
carried out in the presence of the stable free radical DPPH
following Hatano’s method (Hatano et al., 1988) using 2-
tert-butyl-4-methoxyphenol (butylated hydroxyl anisole,
BHA), 2-(1,1-dimethylethyl)-1,4-benzenediol (2-tert. butyl
hydroquinone, TBHQ) and ascorbic acid as standards. The
radical scavenging activity (RSA) for methanolic solutions of
compounds ( 2a–c)– (8a–c) at concentrations 25, 50, 75 and
100 lg/ml containing freshly prepared DPPH solution
(0.004% w/v) was carried out and compared with those of
standards BHA and TBHQ. All the test analyses wereperformed on three replicates and results are averaged. The re-
sults in percentage are expressed as the ratio of absorption de-
crease of DPPH in the presence of test compounds and
absorption of DPPH in the absence of test compounds at
517 nm using ELICO SL 171 Mini Spec spectrophotometer.
The percentage scavenging activity of the DPPH free radical
was measured using the following equation
%DPPH radical scavenging
¼ Absorbance of controlAbsorbence of test sample
Absorbance of control
 100
5.3. Antimicrobial assay
The antimicrobial activities (Indian Pharmacopoeia, 1985) of
the compounds prepared in this effort were evaluated using
P. aeruginosa (Gram negative bacteria), Klebsiella pneumoniae
(gram negative bacteria),A. oryzae andA. niger (fungi). An ali-
quot 0.1 ml of each bacterial strain was on nutrient agar while
0.1 ml of the fungal spore suspension was spread on potato
dextrose agar (PDA). An agar-well diffusion test was per-
formed in each case. In these tests, 6 mm wells were produced
by using a sterile cork borer and each well was then inoculated
with 100 ll of each key substance in DMF, resulting in a ﬁnal
concentration of 250 lg/ml, 125 250 lg/ml and 62.5 250 lg/ml.
Nutrient agar plates were incubated at 37 C for 24 h while the
PDA plates incubated at 25 C for 72 h. The zone of inhibition
around the well was determined. Gentamycin and ﬂucanozole
were used as the reference antibacterial and antifungal agents,
respectively.
Synthesis, antimicrobial and antioxidant activities S5096. Conclusion
Antioxidants may be classiﬁed according to their mode of ac-
tion as being free radical terminators, chelators of metal ions
involved in catalyzing lipid oxidation or radical scavengers
that react with oxygen in closed systems. In this study we pre-
sented the antioxidant activity of synthesized compounds using
two comparable methods, 1,1-diphenyl-2-picrylhydrazyl radi-
cal-scavenging activity test and assay for evaluation of reduc-
ing power. The synthesized compounds scavenged the DPPH
radical reduced Fe+3 cations in a concentration dependent
manner. These experiments were prompted, ﬁrst, by the up-
surge of interest in the contribution of reactive oxygen species
and oxygen-derived free radical to tissue damage and human
diseases, and, second, by the increasing awareness antioxidants
that counteract oxidative stress may exert valuable protective
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